Hengbang Wang

机构：Ascepion Pharmaceuticals (China), Department of Health of Guangdong Province · ORCID：0000-0003-3740-9056

发表论文 96 篇 · 总被引 803 次 · h-index 13

代表论文

• Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib (2024 · JAMA Oncology · 被引 30)
• Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax (2024 · Blood · 被引 8)
• Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study (2025 · Med · 被引 6)
• A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors. (2025 · Journal of Clinical Oncology · 被引 5)
• Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research (2025 · Signal Transduction and Targeted Therapy · 被引 4)
• Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis (2024 · Blood · 被引 3)